Rotundic acid

Synonyms: 铁冬青酸
Rotundic acid 是一种口服有效的三萜类化合物,与 PTP1B 的 Kd 值为 51.3 µM,可下调 AKT/mTOR 促存活通路并调控 MAPK 通路,诱导细胞周期 S 期阻滞、DNA 损伤和细胞凋亡 (apoptosis),抑制癌细胞的迁移、侵袭、血管生成及增殖,同时提高瘦素敏感性、调节肠道菌群、减少细胞衰老,可用于肝细胞癌、肥胖症、衰老、急性肺损伤及 2 型糖尿病的相关研究。
产品编号: MS-K31669 纯度: 98.41% CAS No.: 20137-37-5 分子式: C30H48O5 分子量: 488.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Rotundic acid 是一种口服有效的三萜类化合物,与 PTP1B 的 Kd 值为 51.3 µM,可下调 AKT/mTOR 促存活通路并调控 MAPK 通路,诱导细胞周期 S 期阻滞、DNA 损伤和细胞凋亡 (apoptosis),抑制癌细胞的迁移、侵袭、血管生成及增殖,同时提高瘦素敏感性、调节肠道菌群、减少细胞衰老,可用于肝细胞癌、肥胖症、衰老、急性肺损伤及 2 型糖尿病的相关研究。

生物实验数据

生物活性 Rotundic acid is an orally active triterpenoid with a Kd value of 51.3 µM for PTP1B that downregulates the AKT/mTOR pro-survival pathway and regulates the MAPK pathway, induces S-phase cell cycle arrest, DNA damage, and apoptosis, inhibits cancer cell migration, invasion, angiogenesis, and proliferation, and simultaneously enhances leptin sensitivity, modulates gut microbiota, and reduces cellular senescence, making it applicable to research on hepatocellular carcinoma, obesity, aging, acute lung injury, and type 2 diabetes.
IC50 & Target

mTOR

 

p38 MAPK

 

体外研究
(In Vitro)

Rotundic acid (10-30 μM) 可剂量依赖性地抑制 HUVEC 细胞的迁移。
Rotundic acid (0-1000 μM) 是人源 PTP1B 的非竞争性抑制剂,其最佳抑制作用依赖于该蛋白的 C 端,对 PTP1B1-298、PTP1B1-321 和 PTP1B1-393 的 IC50 值分别为 2 mM、481.8 μM 和 443.7 μM。
Rotundic acid (3.125-100 μM; 48 h) 可显著延长 BY4741 酵母细胞的复制寿命,在 12.5 μM 浓度下最大延长幅度达 135%。
Rotundic acid (5-20 μM; 24 h) 可降低衰老 WI-38 人胚肺成纤维细胞的细胞衰老水平,表现为 SA-β-gal 阳性细胞减少;同时在 12.5 μM 浓度下可促进细胞增殖。
Rotundic acid (15-60 μM; 24 h) 对 RAW264.7 小鼠巨噬细胞无细胞毒性,在孵育 24 h 后,其浓度最高可达 60 μM。
Rotundic acid (15-60 μM; 1 h pretreatmen) 可呈剂量依赖性降低 LPS (MS-X54539) 刺激的 RAW264.7 小鼠巨噬细胞中亚硝酸盐的生成。
Rotundic acid (15-60 μM; 1 h pretreatment) 可抑制 LPS 诱导 RAW264.7 小鼠巨噬细胞中 TNF-α 和 IL-6 的释放。
Rotundic acid (15-60 μM; 1 h pretreatment) 可调控 LPS 刺激的 RAW264.7 小鼠巨噬细胞中的多条炎症信号通路,包括抑制 NF-κB、MAPK 及 PI3K/Akt/mTOR 的激活、上调 Keap-1/Nrf2/HO-1 信号通路并降低 TLR4 的表达。
Rotundic acid (15-60 μM; 1 h pretreatment) 可降低 LPS 诱导 RAW264.7 小鼠巨噬细胞的 NO 释放量、ROS 生成量及细胞内 Ca2+ 水平。
Rotundic acid 对 Daoy、Hep-2 和 MCF-7 人肿瘤细胞系具有显著的细胞毒活性。

Cell Viability Assay

Cell Line: RAW264.7 murine macrophages
Concentration: 15, 30, 60 μM
Incubation Time: 24 h
Result: Showed no cytotoxic effect on RAW264.7 macrophages at all tested concentrations, with cell viability remaining above 80% relative to the control group.

ELISA Assay

Cell Line: LPS-stimulated RAW264.7 murine macrophages
Concentration: 15-60 μM
Incubation Time: 1 h pretreatment, followed by 18 h LPS stimulation
Result: Significantly decreased the release of TNF-α and IL-6 at all tested concentrations, with consistent, significant inhibition across doses.
Increased TNF-α and IL-6 release strongly when LPS was applied alone.
体内研究
(In Vivo)

Rotundic acid (50 mg/kg;腹腔注射;每 2 天 1 次;持续 60 天) 在人肝癌 HepG2 细胞异种移植 Balb/c 裸鼠模型中实现了 75.6%的肿瘤生长抑制率,同时还可降低肿瘤重量、抑制增殖与血管生成并诱导细胞凋亡,且不会导致显著的体重下降。
Rotundic acid (40 mg/kg;腹腔注射;每月 1 周;持续 6 个月) 可使自然衰老的雄性 C57BL/6J 小鼠的平均寿命延长 16.2%,并改善其衰老相关功能指标。
Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 可使高脂饮食诱导的肥胖小鼠体重最高降低 26.3%,并呈剂量依赖性减少其食物摄入量。
Rotundic acid (腹腔注射;40 mg/kg;每日 1 次;连续 14 天) 可使平均体重约为 58 g 的高脂饮食诱导肥胖小鼠的体重降低 25.1%,同时减少其食物摄入量、降低脂肪组织重量并下调血浆瘦素水平。
Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 对正常瘦型雄性 C57BL/6N 小鼠的体重、食物摄入量或脂肪组织质量均无影响。
Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 可改善高脂饮食诱导肥胖小鼠的葡萄糖稳态与胰岛素敏感性。
Rotundic acid (20-40 mg/kg;腹腔注射) 可使二甲苯诱导的小鼠耳肿胀减轻 80%以上,并改善相关的病理性组织损伤。
Rotundic acid (20-40 mg/kg;腹腔注射) 可将 LPS 诱导的内毒素休克小鼠的 144 小时存活率提升至 30%。
Rotundic acid (10-40 mg/kg;腹腔注射) 可降低 LPS 诱导的炎症标志物水平,改善肺功能损伤,并缓解小鼠急性肺损伤模型中的肺部病理性损伤。
Rotundic acid (40 mg/kg;灌胃;每日;8 周) 可改善 2 型糖尿病大鼠的糖脂代谢、降低血压、保护其免受心血管及肝肾损伤、减轻氧化应激与炎症反应,并恢复由高脂饮食联合低剂量链脲佐菌素诱导的肠道菌群失调。

Animal Model: Balb/c nude (male, 5 weeks old, subcutaneous HepG2 cell xenograft)
Dosage: 50 mg/kg
Administration: i.p.; every 2 days; 60 days
Result: Reduced mean tumor volume to 78.95 mm3 (vs. 323.64 mm3 in controls), achieving 75.6% tumor growth inhibition.
Reduced tumor weights significantly compared to controls.
Showed no significant body weight loss.
Reduced expression of proliferation marker Ki-67, angiogenesis marker CD-31, phosphorylated AKT, and phosphorylated mTOR in tumor tissue.
Increased expression of phosphorylated p38 MAPK in tumor tissue.
Induced apoptosis via increased cleaved PARP and cleaved caspase-3 in tumor tissue.
Animal Model: C57BL/6N (male, 8 weeks old, high-fat diet-induced obese)
Dosage: 40 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced body weight in a dose-dependent manner, with the 40 mg/kg dose causing a 26.3% decrease.
Reduced daily food intake by 62.3% in the first week of 40 mg/kg treatment.
Animal Model: BALB/c (male, 18-20 g, LPS-induced acute lung injury model)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.p.; two doses: 2 hours before LPS, 4 hours after LPS
Result: Decreased LPS-induced increases in blood lymphocytes, neutrophils, and white blood cells.
Reduced levels of TNF-α, IL-6, and IL-1β in serum, bronchoalveolar lavage fluid, and lung tissue homogenate.
Reduced myeloperoxidase activity in lung tissue.
Significantly recovered mouse lung function including peak expiratory flow, dynamic lung compliance, inspiratory resistance, expiratory resistance, and minute ventilation volume.
Ameliorated LPS-induced alveolar interstitial exudation, alveolar structural destruction, and inflammatory cell infiltration observed via H&E staining.
Animal Model: Sprague-Dawley (5-week-old male, weight 180-220 g, type 2 diabetes induced by high-fat diet + low-dose streptozotocin)
Dosage: 40 mg/kg
Administration: i.g.; daily; 8 weeks
Result: Increased body weight compared to T2D model rats.
Decreased water intake and increased food intake compared to T2D model rats.
Reduced fasting glucose, glycated hemoglobin A1c (HbA1c), and insulin levels compared to T2D model rats.
Reduced glucose area under the curve (AUC) for OGTT and ITT, and reduced HOMA-IR index compared to T2D model rats.
Significantly reduced serum total glyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and free fatty acid (FFA) levels, and increased high-density lipoprotein cholesterol (HDL-C) levels compared to T2D model rats.
Reduced systolic blood pressure (SYS), diastolic blood pressure (DIA), mean arterial pressure (MAP), and serum angiotensin-2 (ANG-2) levels compared to T2D model rats.
Significantly reduced serum myocardial enzymes (α-HBDH: 151.9 U/L, CK: 0.418 U/L, CK-MB: 191.7 U/L, LDH: 1854.0 U/L), C-reactive protein (CRP: 422.7 pg/mL), endothelin-1 (ET-1: 48.9 pg/mL), alanine aminotransferase (ALT: 44.6 IU/L), aspartate aminotransferase (AST: 99.32 IU/L), alkaline phosphatase (ALP: 15.1 KU/100 mL), uric acid (UA: 131.0 μmol/L), and urea nitrogen (BUN: 5.3 mmol/L) compared to T2D model rats.
Increased serum superoxide dismutase (SOD: 246.7 U/L) and interleukin-4 (IL-4: 55.2 pg/mL) levels compared to T2D model rats.
Decreased serum malondialdehyde (MDA: 4.73 nmol/mL), tumor necrosis factor-α (TNF-α: 259.1 pg/mL), interferon-γ (INF-γ: 16.6 pg/mL), interleukin-1β (IL-1β: 11.0 pg/mL), and interleukin-6 (IL-6: 8.7 pg/mL) levels compared to T2D model rats.
Increased Chao1 and Shannon α-diversity indices compared to T2D model rats.
Reversed the elevated Firmicutes-to-Bacteroidetes ratio seen in T2D model rats.
Increased relative abundances of beneficial/commensal genera Prevotella, Ruminococcus, Leuconostoc, and Streptococcus compared to T2D model rats.
Decreased relative abundances of opportunistic pathogen genera Klebsiella and Proteus compared to T2D model rats.
性状 固体
颜色 White to off-white

化学信息

分子量 488.70
分子式 C30H48O5
CAS No. 20137-37-5
别名 铁冬青酸

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 10 mg/mL (20.46 mM), Suspension.
10% DMSO+90% Corn Oil: 2.5 mg/mL (5.12 mM), Sonication is recommended.
10% DMSO+90% Saline: < 10 mg/mL (20.46 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (204.62 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0462 mL10.2312 mL20.4625 mL51.1561 mL
5 mM0.4092 mL2.0462 mL4.0925 mL10.2312 mL
10 mM0.2046 mL1.0231 mL2.0462 mL5.1156 mL
15 mM0.1364 mL0.6821 mL1.3642 mL3.4104 mL
20 mM0.1023 mL0.5116 mL1.0231 mL2.5578 mL
25 mM0.0818 mL0.4092 mL0.8185 mL2.0462 mL
30 mM0.0682 mL0.3410 mL0.6821 mL1.7052 mL
40 mM0.0512 mL0.2558 mL0.5116 mL1.2789 mL
50 mM0.0409 mL0.2046 mL0.4092 mL1.0231 mL
60 mM0.0341 mL0.1705 mL0.3410 mL0.8526 mL
80 mM0.0256 mL0.1279 mL0.2558 mL0.6395 mL
100 mM0.0205 mL0.1023 mL0.2046 mL0.5116 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

铁冬青酸 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础